U.S. markets close in 10 minutes

Avacta Group Plc (AVCT.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
100.00-1.00 (-0.99%)
At close: 05:07PM BST

Avacta Group Plc

Thorp Arch Estate
Unit 20 Ash Way
Wetherby LS23 7FA
United Kingdom
44 1904 217 070

Full Time Employees133

Key Executives

NameTitlePayExercisedYear Born
Dr. David Alastair SmithCEO & Exec. Director418kN/AN/A
Mr. Tony GardinerCFO, Company Sec. & Exec. Director258kN/A1971
Ms. Emma WrightGroup In-House CounselN/AN/AN/A
Mr. Michael VinegradGroup Communications DirectorN/AN/AN/A
Dr. Matt JohnsonChief Scientific Officer of DiagnosticsN/AN/AN/A
Dr. Neil BellChief Devel. Officer of TherapeuticsN/AN/A1958
Dr. Fiona McLaughlin FSB, Ph.D.Chief Scientific Officer of Therapeutics DivisionN/AN/A1970
Mr. Marc GreenHead of Product Devel. - DiagnosticsN/AN/AN/A
Gemma WilsonHead of QA/RA - DiagnosticsN/AN/AN/A
Mr. Petros SarantosHead of Product Management - DiagnosticsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Corporate Governance

Avacta Group Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.